# CNISP Laboratory Surveillance 2019

Surveillance Period – January 1 to December 31

| CNISP Project | MRSA/MSSA (CORE Surveillance) | | VRE (CORE Surveillance) | | CDI (CORE Surveillance) | | CPO |
|---|---|---|---|---|---|---|---|
| **Surveillance Information** | *See* **2019 Surveillance Protocol for Methicillin-Resistant and Methicillin-Susceptible *Staphylococcus aureus* Bloodstream Infections in CNISP Hospitals** | | *See* **Surveillance of Vancomycin Resistant Enterococci Bloodstream Infections in CNISP Hospitals** | | *See* **Surveillance for *Clostridium difficile* infection (CDI)** | | *See* **Surveillance Protocol for Carbapenemase-Producing Organisms (CPO) in CNISP Healthcare Facilities** |
| **Data and Isolate/Specimen Submission Dates** | **Surveillance Period** | **Data/Lab Submission Deadline** | **Surveillance Period** | **Data/Lab Submission Deadline** | **Surveillance Period** | **Data Submission Deadline** | **Send eligible isolates to the NML as soon as possible.** Send shipment at least once every three months.<br><br>Patient specimens with eligible *Enterobacterales* and/or *Acinetobacter* spp. (as per *Appendix A*) will be identified by the hospital microbiology laboratory and sent to the NML with a minimum data set (*Appendix B*) for detection or confirmation of carbapenemase production.<br><br>A patient questionnaire (*Appendix C*) should be completed for all carbapenemase-producing *Enterobacterales* and/or *Acinetobacter* spp. Please ensure that data submitted on *Appendix B* matches data submitted on the patient questionnaire (*Appendix C*) (e.g. age, sex, pathogen, site of isolation, etc.).<br><br>All patient questionnaires should be submitted on a quarterly basis by email to CNISP at phac.cnisp-pcsin.aspc@canada.ca |
| | **Jan. 01 – Mar. 31, 2019** | **NOT LATER THAN June 30, 2019** | **Jan. 01 – Mar. 31, 2019** | **NOT LATER THAN June 30, 2019** | **Jan. 01 – Mar. 31, 2019** | **NOT LATER THAN June 30, 2019** | |
| | **Apr. 01 – June 30, 2019** | **NOT LATER THAN Sept. 30, 2019** | **Apr. 01 – June 30, 2019** | **NOT LATER THAN Sept. 30, 2019** | **Apr. 01 – June 30, 2019** | **NOT LATER THAN Sept. 30, 2019** | |
| | **July 01 – Sep. 30, 2019** | **NOT LATER THAN Dec. 31, 2019** | **July 01 – Sep. 30, 2019** | **NOT LATER THAN Dec. 31, 2019** | **July 01 – Sep. 30, 2019** | **NOT LATER THAN Dec. 31, 2019** | |
| | **Oct. 01 – Dec. 31, 2019** | **NOT LATER THAN Mar. 31, 2020** | **Oct. 01 – Dec. 31, 2019** | **NOT LATER THAN Mar. 31, 2020** | **Oct. 01 – Dec. 31, 2019** | **NOT LATER THAN Mar. 31, 2020** | |
| | | | | | **Adult CDI stools to be submitted to NML by July 31 of each year.**<br><br>**Pediatric CDI stools to be submitted to NML by the data submission deadlines above and NO LATER THAN March 31 the following year.** | | |
| **Laboratory Surveillance** | One blood isolate is required for every eligible MRSA BSI case.<br><br>**Please do NOT send MSSA isolates to the NML.**<br><br>In the case of a new infection in the same patient in the same calendar year, please indicate the patient's previous unique ID on the shipping form (*Appendix 2*). | | One blood isolate is required for every eligible VRE BSI case.<br><br>In the case of a new infection in the same patient in the same calendar year, please indicate the patient's previous unique ID on the shipping form (*Appendix 4*). | | **Adult – Targeted:** (≥ 18 years): will run from Mar 01 to Apr 30 of each year.<br><br>**Pediatric – Targeted:** (≥12 months and <18 years): will run from Jan 01 to Dec 31 of each year.<br><br>One stool sample is required for every **lab eligible** CDI case. | | All *Enterobacterales* and *Acinetobacter* spp. that meet at least one of the three laboratory testing criteria for confirmation of carbapenem resistance or carbapenemase production (see *Appendix A*).<br><br>If there are multiple isolates from one patient and laboratories are only sending one isolate, please submit the isolate from the **most invasive specimen**, otherwise please submit all isolates.<br><br>**Environmental Sampling:**<br>**If possible**, consider screening drains at discharge for CPO positive patients. Swab all drains in the patient room and bathroom before a cleaning protocol is implemented. Complete and send Appendix B to the NML along with the CPO positive environmental swab(s). |
| **CHEC ID or Unique Patient Identifier (UPI) Format** | _____ 19 _____<br>**(CHEC site #) (year) (case #)**<br>e.g. 01C19001 | | _____ 19 _____<br>**(CHEC site #) (year) (case #)**<br>e.g. 01C19001 | | _____ 19 _____<br>**(CHEC site #) (year) (case #)**<br>e.g. 01C19001 | | _____ 19 _____<br>**(CHEC site #) (year) (case #)**<br>e.g. 01C19001<br><br>When multiple isolates are submitted for the same patient in the same surveillance year, please indicate by adding a suffix A or B etc. to the case number (e.g. 01C19001A and 01C19001B).<br><br>**Environmental Sampling:**<br>Use the same unique PID assigned to the patient whose room was swabbed and add a suffix E1 or E2 etc. to the case number (e.g. 01C19001E1 and 01C19001E2). |
| **Shipping Requirements** | Eligible MRSA isolates are to be properly labelled (*in indelible ink/marker*) with the assigned **CHEC ID** and as **MRSA.**<br><br>Ensure that the assigned **CHEC ID** corresponds with the **UPI** on the patient questionnaire (See protocol - *Appendix 3*).<br><br>Isolates can be collected for bulk shipment to the NML at the end of each next quarter.<br><br>The standardized shipping form (see protocol – *Appendix 2*) **must** be included in the parcel. | | Eligible VRE isolates are to be properly labelled (*in indelible ink/marker*) with the assigned **CHEC ID** and as **VRE.**<br><br>Ensure that the assigned **CHEC ID** corresponds with the **UPI** on the patient questionnaire (see protocol - *Appendix 2*).<br><br>Isolates can be collected for bulk shipment to the NML at the end of each next quarter.<br><br>The standardized shipping form (see protocol - *Appendix 4*) **must** be included in the parcel. | | Ensure that the assigned **CHEC ID** on the specimen vial corresponds with the **UPI** on the patient questionnaire.<br><br>The standardized shipping form (see protocol - *Appendix 7*) **must** be included in the parcel. | | Eligible CRGN isolates are to be properly labelled (*in indelible ink/marker*) with the assigned **UPI**.<br><br>Send isolates to the NML and include the data collection form (*Appendix B*) in the parcel.<br><br>To avoid receiving duplicate isolates at the NML, **please alert the NML if the shipped isolate(s) were sent to your provincial laboratory** as they may have also sent these isolates to the NML for testing. These isolates would have been assigned an NML number (e.g. N19-01234). **If you have an NML number, please include it on *Appendix B* with the CNISP PID**. |

Email an electronic copy of the completed standardized laboratory shipping forms to the NML at phac.nml.ARNI-RAIN.lnm.aspc@canada.ca.

(Updated January 2019)